Matrix Trust Company’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$3.16M Sell
12,555
-989
-7% -$213K 0.46% 31
2026
Q1
$2.95M Buy
13,544
+304
+2% +$67.4K 0.49% 29
2025
Q4
$3.02M Sell
13,240
-1,025
-7% -$233K 0.5% 27
2025
Q3
$3.3M Sell
14,265
-329
-2% -$67K 0.52% 26
2025
Q2
$2.71M Buy
14,594
+671
+5% +$125K 0.43% 32
2025
Q1
$2.92M Buy
13,923
+84
+0.6% +$16.3K 0.49% 25
2024
Q4
$2.46M Buy
13,839
+420
+3% +$77.2K 0.43% 29
2024
Q3
$2.65M Buy
13,419
+102
+0.8% +$19K 0.5% 25
2024
Q2
$2.28M Buy
13,317
+89
+0.7% +$14.7K 0.52% 22
2024
Q1
$2.41M Buy
13,228
+14
+0.1% +$2.41K 0.54% 19
2023
Q4
$2.05M Sell
13,214
-88
-0.7% -$12.8K 0.48% 25
2023
Q3
$1.98M Buy
13,302
+141
+1% +$20.7K 0.52% 22
2023
Q2
$1.77M Buy
13,161
+484
+4% +$71K 0.46% 28
2023
Q1
$2.02M Buy
12,677
+840
+7% +$128K 0.54% 18
2022
Q4
$1.91M Buy
11,837
+3,675
+45% +$563K 0.48% 19
2022
Q3
$1.09M Buy
8,162
+2,499
+44% +$359K 0.31% 24
2022
Q2
$867K Buy
5,663
+3,045
+116% +$465K 0.24% 24
2022
Q1
$424K Buy
+2,618
New +$380K 0.1% 20

Other funds holding ABBV

Matrix Trust Company's ABBV Position: Q2 2026 in Review

Matrix Trust Company reduced its AbbVie (ABBV) stake by 7.3% in Q2 2026, selling an estimated $213K and leaving 12,555 shares worth $3.16M. The position accounts for 0.46% of the portfolio, ranked #31.

Matrix Trust Company first reported a position in ABBV in Q1 2022 and has held it in 18 quarters since. The position peaked at $3.3M in Q3 2025. 2,121 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Matrix Trust Company held 12,555 shares of AbbVie worth $3.16M as of Q2 2026.
  • Matrix Trust Company sold 989 AbbVie shares in Q2 2026, an estimated $213K.
  • AbbVie made up 0.46% of Matrix Trust Company's portfolio in Q2 2026, its #31 holding.
  • Matrix Trust Company first reported a position in AbbVie in Q1 2022 and has held it in 18 quarters since.
  • Matrix Trust Company's AbbVie position peaked at $3.3M in Q3 2025.
  • 2,121 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Matrix Trust Company's 13F filing for Q2 2026, filed 9 Jul 2026.